Aspirin slows DNA mutations in pre-cancerous conditions

| | June 19, 2013
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The following is an excerpt.

Researchers analyzed biopsy samples from 13 patients with a pre-cancerous condition known as Barrett’s esophagus, who were tracked for six to 19 years. The goal of the analysis was to track the rate of mutations in tissues sampled at different times. They performed a crossover study in which some patients started taking daily aspirin for several years and then stopped, while others started taking aspirin for the first time during observation.

The team found that biopsies taken while patients were on an aspirin had accumulated new mutations about ten times slower than biopsies obtained during years when patients were not taking aspirin.

Read the full story here: Aspirin Slows DNA Mutations In Pre-Cancerous Conditions

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend